The cholesterol paradox is flawed; cholesterol must be lowered in dialysis patients

Seminars in Dialysis

Volumn 20, Issue 6, 2007, Pages 504-509

  Wan, Ray K ^a   Mark, Patrick B ^a   Jardine, Alan G ^a,b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL;

BIOLOGICAL MODEL; BLOOD; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; DYSLIPIDEMIA; HUMAN; HYPERLIPIDEMIA; INFLAMMATION; MALNUTRITION; RENAL REPLACEMENT THERAPY; REVIEW; RISK FACTOR;

CARDIOVASCULAR DISEASES; CHOLESTEROL; CLINICAL TRIALS AS TOPIC; DYSLIPIDEMIAS; HUMANS; HYPERLIPIDEMIAS; INFLAMMATION; KIDNEY FAILURE, CHRONIC; MALNUTRITION; MODELS, CARDIOVASCULAR; RENAL DIALYSIS; RISK FACTORS;

EID: 35948973610     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2007.00359.x     Document Type: Review

References (52)

1. US Renal Data System: USRDS 1999 annual data report. Am J Kidney Dis 34 (2 Suppl. 1 S87 S94, 1999
2. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE : The prognostic importance of left ventricular geometry in uremic cardiomyopathy. J Am Soc Nephrol 5 : 2024 2031, 1995
3. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY : Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351 : 1296 1305, 2004
4. Liu J, Rosner MH : Lipid Abnormalities Associated with End-Stage Renal Disease. Semin Dial 19 : 32 40, 2006
5. Kronenberg F, Lingenehl A, Neyer U, Lhotta K, Konig P, Auinger M, Wiesholzer M, Andersson H, Dieplinger H : Prevalence of dyslipidemic risk factors in hemodialysis and CAPD patients. Kidney Int Suppl 84 : S113 S116, 2003
6. Prichard SS : Impact of dyslipidemia in end-stage renal disease. J Am Soc Nephrol 14 (9 Suppl. 4 S315 S320, 2003
7. Scandinavian Simvastatin Survival Study Group : Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 334 : 1383 1389, 1994
8. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ : Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333 : 1301 1307, 1995
9. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto Jr. AM : Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279 : 1615 1622, 1998
10. Heart Protection Study Collaborative Group : MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 : 7 22, 2002
11. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E : The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators N Engl J Med 335 : 1001 1009, 1996
12. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group : Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 339 : 1349 1357, 1998
13. Lowrie EG, Lew NL : Death risk in hemodialysis patients: The predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 15 : 458 482, 1990
14. Degoulet P, Legrain M, Reach I, Aime F, Devries C, Rojas P, Jacobs C : Mortality risk factors in patients treated by chronic hemodialysis. Report of the Diaphane collaborative study. Nephron 31 : 103 110, 1982
15. Nishizawa Y, Sholi T, Ishimura E, Inaba M, Morii H : Paradox of risk factors for cardiovascular mortality in uremia: is a higher cholesterol level better for atherosclerosis in uremia? Am J Kidney Dis 38 (4 Suppl. 1 S4 S7, 2001
16. Avram MM, Bonomini LV, Sreedhara R, Mittman N : Predictive value of nutritional markers (albumin, creatinine, cholesterol, and hematocrit) for patients on dialysis for up to 30 years. Am J Kidney Dis 28 : 910 917, 1996
17. Seliger SL, Stehman-Breen CO : Are HMG-CoA reductase inhibitors underutilized in dialysis patients? Semin Dial 16 : 179 185, 2003
18. Liu Y, Coresh J, Eustace JA, Longenecker JC, Jaar B, Fink NE, Tracy RP, Powe NR, Klag MJ : Association between cholesterol level and mortality in dialysis patients. JAMA 291 : 451 459, 2004
19. Seliger SL, Weiss NS, Gillen DL, Kestenbaum B, Ball A, Sherrard DJ, Stehman-Breen CO : HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int 61 : 297 304, 2002
20. Ichihara A, Hayashi M, Ryuzaki M, Handa M, Furukawa T, Saruta T : Fluvastatin prevents development of arterial stiffness in haemodialysis patients with type 2 diabetes mellitus. Nephrol Dial Transplant 17 : 81513 81517, 2002
21. Baigent C, Landray M, Leaper C, Altmann P, Armitage J, Baxter A, Cairns HS, Collins R, Foley RN, Frighi V, Kourellias K, Ratcliffe PJ, Rogerson M, Scoble JE, Tomson CR, Warwick G, Wheeler DC : First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. Am J Kidney Dis 45 : 473 484, 2005
22. Harris KP, Wheeler DC, Chong CC : A placebo-controlled trial examining atorvastatin in dyslipidaemic patients undergoing CAPD. Kidney Int 61 : 81469 81474, 2002
23. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, Ritz E : German Diabetes and Dialysis Study Investigators: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353 : 238 248, 2005
24. Holdaas H, Fellstrom B, Jardine AG, Holme I, Nyberg G, Fauchald P, Gronhagen-Riska C, Madsen S, Neumayer H, Cole E, Maes B, Ambuhl P, Olsson AG, Hartmass A, Solbu DO, Pedersen TR : the Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators: Effect of fluvastatin on cardiac outcomes in renal transplant recipients: A multicentre, randomised, placebo-controlled trial. Lancet 361 : 2024 2031, 2003
25. Wiviott SD, Cannon CP, Morrow DA, Ray KK, Pfeffer MA, Braunwald E : PROVE IT-TIMI 22 Investigators. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy. J Am Coll Cardiol 46 : 1411 1416, 2005
26. Keane WF, Collins AJ : Influence of co-morbidity on mortality and morbidity in patients treated with hemodialysis. Am J Kidney Dis 24 : 1010 1018, 1994
27. Qureshi AR, Alvestrand A, Danielsson A, Divino-Filho JC, Gutierrez A, Lindholm B, Bergstrom J : Factors influencing malnutrition in hemodialysis patients: A cross-sectional study. Kidney Int 53 : 773 782, 1998
28. Kaysen GA, Stevenson FT, Depner TA : Determinants of albumin concentration in hemodialysis patients. Am J Kidney Dis 29 : 658 668, 1997
29. Iseki K, Yamazato M, Tozawa M, Takishita S : Hypocholesterolemia is a significant predictor of death in a cohort of hemodialysis patients. Kidney Int 61 : 1887 1893, 2002
30. Albert MA, Danielson E, Rifai N, Ridker PM : PRINCE Investigators: Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 286 : 64 70, 2001
31. Chang JW, Yang WS, Min WK, Lee SK, Park JS, Kim SB : Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients. Am J Kidney Dis 39 : 81213 81217, 2002
32. Vernaglione L, Cristofano C, Muscogiuri P, Chimienti S : Does atorvastatin influence serum C-reactive protein levels in patients on long-term hemodialysis? Am J Kidney Dis 43 : 471 478, 2004
33. Bologa RM, Levine DM, Parker TS, Cheigh JS, Serur D, Stenzel KH, Rubin AL : Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis 32 : 107 114, 1998
34. Kopple JD : The phenomenon of altered risk factor patterns or reverse epidemiology in persons with advanced chronic kidney failure. Am J Clin Nutr 81 : 1257 1266, 2005
35. Nishizawa Y, Shoji T, Kakiya R, Tsujimoto Y, Tabata T, Ishimura E, Nakatani T, Miki T, Inaba M : Non-high-density lipoprotein cholesterol (non-HDL-C) as a predictor of cardiovascular mortality in patients with end-stage renal disease. Kidney Int 63 (Suppl. 84 117 120, 2003
36. Inoue T, Hayashi M, Takayanagi K, Morooka S : Lipid-lowering therapy with fluvastatin inhibits oxidative modification of low density lipoprotein and improves vascular endothelial function in hypercholesterolemic patients. Atherosclerosis 160 : 8369 8376, 2002
37. Calabro P, Yeh ET : The pleiotropic effects of statins. Curr Opin Cardiol 20 : 541 546, 2005
38. Liao JK : Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol. Am J Cardiol 96 : 24F 33F, 2005
39. National Kidney Foundation : K/DOQI Clinical Practice Guidelines for Managing Dyslipidemias in Chronic Kidney Disease. Am J Kidney Dis 41 (Suppl. 3 S1 S92, 2003
40. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults : Executive Summary on the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Panel III). JAMA 285 : 2486 2497, 2001
41. Young EW, Goodkin DA, Mapes DL, Port FK, Keen ML, Chen K, Maroni BL, Wolfe RA, Held PJ : The Dialysis Outcomes and Practice Patterns Study (DOPPS): An international haemodialysis study. Kidney Int 74 (Suppl S74 S81, 2000
42. Mason NA, Bailie GR, Satayathum S, Bragg-Gresham JL, Akiba T, Akizawa T, Combe C, Rayner HC, Saito A, Gillespie BW, Young EW : HMG-CoEnzymeA Reductase Inhibitor Use Is Associated With Mortality Reduction in Haemodialysis Patients. Am J Kidney Dis 45 : 119 126, 2004
43. Tonelli M, Isles C, Curhan GC, Tonkin A, Pfeffer MA, Shepherd J, Sacks FM, Furberg C, Cobbe SM, Simes J, Craven T, West M : Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 110 : 1557 1563, 2004
44. Holdaas H, Fellstrom B, Cole E, Nyberg G, Olsson AG, Pedersen TR, Madsen S, Gronhagen-Riska C, Neumayer H, Maes B, Ambuhl P, Hartmann A, Staffler B, Jardine AG : The Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators: Long-term Cardiac Outcomes in Renal Transplant Recipients Receiving Fluvastatin: The ALERT Extension Study. Am J Transplant 5 : 2929 2936, 2005
45. Budoff MJ, Lane KL, Bakhsheshi H, Mao S, Grassmann BO, Friedman BC, Brundage BH : Rates of progression of coronary calcium by electron beam tomography. Am J Cardiol 86 : 8 11, 2000
46. Callister TQ, Raggi P, Cooil B, Lippoli NJ, Russo DJ : Effect of HMG-CoA reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography. N Engl J Med 339 : 1972 1978, 1998
47. Qunibi WY : Dyslipidemia and progression of cardiovascular calcification (CVC) in patients with end-stage renal disease (ESRD). Kidney Int 95 (Suppl S43 S50, 2005
48. Raggi P, Boulay A, Chasan-Taber S, Amin N, Dillon M, Burke SK, Chertow GM : Cardiac calcification in adult hemodialysis patients: A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 39 : 695 701, 2002
49. Chertow GM, Burke SK, Raggi P : Treat to Goal Working Group: Sevelamer sttenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62 : 245 252, 2002
50. Nitta K, Akiba T, Nihei H : Colestimide co-administered with atorvastatin attenuates the progression of vascular calcification in hemodialysis patients. Nephrol Dial Transplant 19 : 2156, 2004
51. Tamashiro M, Iseki K, Sunagawa O, Inoue T, Higa S, Afuso H, Fukiyama K : Significant association between the progression of coronary artery calcification and dyslipidemia in patients on chronic hemodialysis. Am J Kidney Dis 38 : 64 69, 2001
52. Fellstrom B, Zannad F, Schmieder R, Holdaas H, Jardine A, Rose H, Wilpshaar W : AURORA Study Group: Effect of rosuvastatin on outcomes in chronic haemodialysis patients - design and rationale of the AURORA study. Curr Control Trials Cardiovasc Med 6 : 9, 2005